GlobalData on MSN12h
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...
Healio8d
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...
Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Pharvaris Outlines 2025 Strategic Priorities
Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership ...
Enid News & Eagle11d
Pharvaris Outlines 2025 Strategic Priorities
Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3 ...